0.06%,0.03% solution nasal spray
5mg/3ml Solution for Atomization
100mg, 250mg oral capsules without dyes or preservatives
Amphotericin B is an antifungal medication often recommended by physicians for the treatment of severe mold and biotoxin-related illnesses. Amphotericin works by damaging the structure of the fungal cell wall, thus slowing the growth of infectious fungi. Mold infections are often coupled with the formation of a highly resistant biofilm. This biofilm usually contributes to chronic inflammation frequently associated with the mold illness Chronic Rhinosinusitis. In a clinical study of Chronic Rhinosinusitis (CRS) treatments with intranasal antifungal agents such as Amphotericin B, patients showed significant improvements in several parameters, including a reduction in inflammatory mucosal thickening. As part of his protocol for the treatment of illnesses caused by mold toxicity, Dr. Neil Nathan recommends the usage of Amphotericin B to target fungal pathogens in the sinuses.
At Forte Rx Compounding Pharmacy, we offer the highest quality compounded Amphotericin B made to order for our patients. Forte Rx Compounding Pharmacy is owned and operated by Dr. Haleh Khatami Pharm.D., an expert in CIRS (chronic inflammatory response syndrome), mold/biotoxin illness, MCAS (mast cell activation syndrome), sinus, and Lyme Disease with over 20 years of experience.
Please contact our clinical department today at (805) 427-9053 and ask to speak with one of our expert mold, biotoxin illness, sinus, and Lyme Disease clinical pharmacists about Compounded Amphotericin B.
 Dixon DM, Walsh TJ. Antifungal Agents. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 76. Available from: https://www.ncbi.nlm.nih.gov/books/NBK8263/
 Brewer, J. H., Thrasher, J. D., & Hooper, D. (2013). Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?. Toxins, 6(1), 66–80. https://doi.org/10.3390/toxins6010066
Clinical study on the effectiveness of intranasal antifungal agent Amphotericin B for the treatment of CRS
Ponikau JU, Sherris DA, Weaver A, Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol. 2005 Jan;115(1):125-31. doi: 10.1016/j.jaci.2004.09.037. PMID: 15637558.
 Dr. Neil Nathan on Amphotericin B for Lyme Patients
Forsgren, S., Nathan, N., & Anderson, W. (2014, July). Townsend Letter. https://www.hoffmancentre.com/wp-content/uploads/pdfs/lyme/Mold%20and%20Mycotoxins%20-%20Often%20Overlooked%20Factors%20in%20Chronic%20Lyme%20Disease.pdf